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L I T E R A T U R E

H I G H L I G H T S
Selected abstracts and commentary

PSYCHIATRY
COMMENTARY
Most guidelines suggest that the most suitable pharmacological treatment for unipolar psychotic depression is a
combination of an antipsychotic and an antidepressant. Wijkstra et al's systematic review challenges that wisdom. They
found no difference in outcomes of patients treated with a combination of antidepressant and antipsychotic drugs,
compared with antidepressant alone. However, it is still too soon to recommend a global change in clinical practice.
Several studies have highlighted the risk of increased suicidal thoughts and behaviours in children and adolescents taking
SSRIs in recent years. Juurlink et al's study has highlighted the almost five-fold risk of completed suicides in the elderly
within the first month of starting SSRIs compared to other antidepressants. The absolute risk is low, however, suggesting
that there is a small group who are more vulnerable.
Depression and dementia often co-exist in older adults and it is sometimes difficult to differentiate the two. This metaanalysis by Ownby et al shows that depression may be an independent risk factor for developing Alzheimer's disease later
in life.
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PHARMACOLOGICAL TREATMENT FOR UNIPOLAR PSYCHOTIC DEPRESSION: SYSTEMATIC
REVIEW AND META-ANALYSIS
BACKGROUND: The optimal pharmacological treatment of
unipolar psychotic depression is u ncertain. AIMS: To
compare the clinical effectiveness of pharmacological
treatments for patients with unipolar psychotic depression.
M E T H O D : Sys te matic re vi e w a nd meta -an al y sis of
randomised controlled trials. R E S U L T S : Ten trials were
included in the review. We found no evidence that the
combination of an antidepressant with an antipsychotic is
more eff ec ti ve than a n anti dep ress ant alo ne. Th is
combination was s tatistically more effective than an
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antipsychotic alone. C O N C L U S I O N S : A n t i d e p r e s s a n t
monotherapy and adding an antipsychotic if the patient does
not respond , or s tar ting wi th t he c om bination of an
antidepressant and an antipsychotic, both appear to be
appropriate options for patients with unipolar psychotic
depression. However, clinically the balance between risks
and benefits may suggest the first option should be preferred
for many patients. Starting with an antipsychotic alone
appears to be inadequate.
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Am J Psychiatry. 2006 May;163(5):813-21
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THE RISK OF SUICIDE WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN THE
ELDERLY
OBJECTIVE: The authors explored the relationship between
the initiation of therapy with selective serotonin reuptake
inhibitor (SSRI) antidepressants and completed suicide in
older patients. METHOD: The authors linked populationbased coroner's records with patient-level prescription data,
physician billing claims, and hospitalization data for more
than 1.2 million Ontario residents 66 years of age and older
from 1992 to 2000. For each suicide case, four closely
m a tch ed c om pari so n sub ject s we re se le ct ed usi ng
propensity score methods. The authors determined the odds
ratio for suicide with SSRIs versus other antidepressant
treatment, calculated at discrete monthly intervals from the
start of treatment. RESULTS: Of 1,329 suicide cases, 1,138
(86%) were each fully matched to four comparison subjects
using propensity scores. During the first month of therapy,
SSRI antidepressants were associated with a nearly fivefold

higher risk of completed suicide than other antidepressants
(adjusted odds ratio: 4.8, 95% confidence interval=1.912.2). The risk was independent of a recent diagnosis of
depression or the receipt of psychiatric care, and suicides of
a violent nature were distinctly more common during SSRI
therapy. Numerous sensitivity analyses revealed consistent
results. No disproportionate suicide risk was seen during the
second and subsequent months of treatment with SSRI
antidepressants, and the absolute risk of suicide with all
antidepressants was low. CONCLUSIONS: Initiation of SSRI
therapy is associated with an increased risk of suicide during
t he fi rst mo nth o f t he ra py com pa r ed wi th ot he r
antidepressants. The absolute risk is low, suggesting that an
idiosyncratic response to these agents may provoke suicide
in a vulnerable subgroup of patients.
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DEPRESSION AND RISK FOR ALZHEIMER DISEASE: SYSTEMATIC REVIEW, META-ANALYSIS,
AND METAREGRESSION ANALYSIS
CONTEXT: A history of depression may increase risk for
developing Alzheimer disease (AD) later in life. Clarifying this
relation might improve understanding of risk factors for and
disease mechanisms in AD. OBJECTIVE: To systematically
review and complete a meta-analysis on the relation of
d epress ion and AD. DATA SOURCE S: We conducted
electronic bibliographic searches of MEDLINE, PsychLit,
EMBASE, and BIOSIS using search terms sensitive to studies
of etiology combined with searches on terms related to
depression and AD and reviewed reference lists of articles.
STUDY SELECTION: Studies with data contrasting depressed
vs nondepressed patients who did and did not later develop
AD were included. Studies that related continuous measures
of depression and cognitive status were excluded. DATA
EXTRACTION: Numerical data were independently extracted
by 3 reviewers. They also rated studies on a scale that
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assessed quality indicators for observational studies. Data on
the interval between observation of depression and the
diagnosis of AD were collected when available. D A T A
SYNTHESIS: Meta-analytic evaluation with random-effects
models resulted in pooled odds ratios of 2.03 (95%
confidence interval, 1.73-2.38) for case-control and of 1.90
(95% confidence interval, 1.55-2.33) for cohort studies.
Findings of increased risk were robust to sensitivity analyses.
Interval between diagnoses of depression and AD was
positively related to increased risk of developing AD,
suggesting that rather than a prodrome, depression may be a
risk factor for AD. CONCLUSIONS: A history of depression
may confer an increased risk for later developing AD. This
relation may reflect an independent risk factor for the
disease.
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